About 10% of people aged 65 and older have Alzheimer’s disease, but the risk varies dramatically by age, sex, and genetics. At 45, a woman’s lifetime risk of developing Alzheimer’s is roughly 1 in 5, while a man’s is about 1 in 10. Those numbers make Alzheimer’s one of the most common serious diseases of aging, and understanding where you fall on the risk spectrum depends on several overlapping factors.
How Risk Climbs With Age
Age is the single strongest predictor of Alzheimer’s, and the numbers tell a steep story. Among people aged 65 to 74, about 5% have Alzheimer’s dementia. That rate jumps to 13% for people aged 75 to 84, and by age 85, roughly one in three people (33%) are living with the disease.
This exponential climb is why Alzheimer’s is sometimes misunderstood as a normal part of aging. It isn’t. Most people, even in the oldest age groups, never develop it. But the odds do shift significantly with each decade of life, which is why population-level projections are so sensitive to how long people live on average.
Women Are Disproportionately Affected
Almost two-thirds of Americans with Alzheimer’s are women. Part of this gap is straightforward: women live longer on average, and longer life means more time spent in the highest-risk age brackets. But longevity doesn’t fully explain the difference.
Starting at age 45, a woman has about a 20% lifetime chance of developing Alzheimer’s compared to roughly 10% for a man. Researchers are still working out why. Hormonal changes after menopause, differences in immune response, and variations in how the brain handles the proteins that drive Alzheimer’s all appear to play a role. Whatever the mechanism, the practical takeaway is clear: women face roughly double the lifetime risk.
Racial and Ethnic Disparities
In the United States, Black Americans are approximately 1.5 to 2 times as likely as white Americans to develop Alzheimer’s and related dementias. The reasons are complex and intertwined with broader health inequities. Higher rates of cardiovascular disease, diabetes, and limited access to early diagnosis and preventive care all contribute. These are largely modifiable risk factors, which means the disparity reflects systemic gaps in healthcare rather than inherent biological differences.
Research on Hispanic and Latino populations is less developed, and existing studies haven’t produced reliable prevalence figures for these groups. What is known is that similar patterns of cardiovascular risk and healthcare access likely influence dementia rates in these communities as well.
Genetics and the APOE Gene
Your genes don’t determine whether you’ll get Alzheimer’s, but one gene in particular shifts the odds. A variant called APOE e4 is the strongest known genetic risk factor for the common, late-onset form of the disease. Everyone inherits two copies of the APOE gene (one from each parent), and the e4 version increases risk in a dose-dependent way.
Carrying one copy of APOE e4 doubles or triples your risk of developing Alzheimer’s. Carrying two copies (one from each parent) makes you 8 to 12 times more likely to develop it. About 25% of people carry at least one copy, while roughly 2 to 3% carry two. Importantly, many people with two copies never develop the disease, and many people with no copies do. APOE e4 loads the dice but doesn’t guarantee the outcome.
Early-Onset Alzheimer’s
About 5% of all Alzheimer’s cases are classified as early-onset, meaning symptoms appear before age 65. That translates to roughly 300,000 people in the United States. Early-onset Alzheimer’s is more likely to have a strong genetic component, sometimes running clearly through families with mutations that virtually guarantee the disease will develop. For most people searching for general prevalence numbers, early-onset cases represent a small but significant fraction of the total.
Mild Cognitive Impairment as a Warning Stage
Mild cognitive impairment, or MCI, sits between normal age-related memory changes and dementia. People with MCI have noticeable problems with memory, language, or decision-making that go beyond what’s expected for their age but don’t yet interfere with daily life. Each year, an estimated 10 to 15% of people living with MCI progress to dementia. Over several years, that annual conversion rate adds up, making MCI one of the strongest individual predictors that Alzheimer’s may follow.
Not everyone with MCI progresses, though. Some people remain stable for years, and a small percentage actually improve. The distinction matters because MCI is the stage where lifestyle interventions (physical exercise, blood pressure control, cognitive engagement) have the most evidence behind them for slowing decline.
Why the Numbers Will Keep Growing
Global dementia cases, of which Alzheimer’s makes up 60 to 70%, are projected to surge from about 57 million in 2019 to nearly 153 million by 2050. That near-tripling sounds alarming, but the driver is demographics, not a worsening epidemic. As populations age worldwide, more people enter the high-risk decades. The age-adjusted rate of dementia is actually expected to hold roughly steady, meaning a 75-year-old in 2050 probably won’t face higher odds than a 75-year-old today. There will simply be far more 75-year-olds.
This distinction matters for how you interpret the headlines. The disease isn’t becoming more common per person. The population is shifting toward the ages where it strikes most often, and that demographic wave will put enormous pressure on healthcare systems, caregiving infrastructure, and families for decades to come.